No Data
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
Wells Fargo Tweaks Signature Picks List, Sells AMZN, STZ While Upping MSFT
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
(LLY) - Analyzing Eli Lilly's Short Interest
Eli Lilly Obesity Drug Shortage Ends Fueling Lawsuit Against FDA
Biogen Announces Detailed Results From The Phase 2/3 DEVOTE Study, Highlighting The Safety And Efficacy Of A Higher Dose Nusinersen Regimen In SMA